{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:25:54Z","timestamp":1784589954692,"version":"3.55.0"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,7,1]]},"DOI":"10.2146\/ajhp120163","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T21:39:29Z","timestamp":1371677969000},"page":"1115-1122","source":"Crossref","is-referenced-by-count":31,"title":["Romidepsin for the treatment of T-cell lymphomas"],"prefix":"10.1093","volume":"70","author":[{"given":"Angie L.","family":"McGraw","sequence":"first","affiliation":[{"name":"Middle Tennessee Medical Center, 1700 Medical Center Parkway, Murfreesboro, TN 37129"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041607525577600_b1-0701115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.hoc.2008.07.014","article-title":"Cutaneous T-cell lymphoma","volume":"22","author":"Lansigan","year":"2008","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019041607525577600_b2-0701115","unstructured":"Cutaneous Lymphoma Foundation. CT-CL-MF fast facts. http:\/\/clfoundation.org\/publications\/CL_fast_facts.pdf (accessed 2011 Jul 19)."},{"key":"2019041607525577600_b3-0701115","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2019041607525577600_b4-0701115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"2019041607525577600_b5-0701115","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick","year":"2001","journal-title":"Blood"},{"key":"2019041607525577600_b6-0701115","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ctrv.2006.08.006","article-title":"Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma","volume":"33","author":"Whittaker","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"2019041607525577600_b7-0701115","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphoma, v.I.2013. www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf (accessed 2013 May 1)."},{"key":"2019041607525577600_b8-0701115","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0889-8588(03)00119-9","article-title":"Peripheral T-cell lymphomas: diagnosis and management","volume":"17","author":"Dearden","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019041607525577600_b9-0701115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCO.0b013e3282ce6f8f","article-title":"Management of peripheral T-cell non-Hodgkin\u2019s lymphoma","volume":"19","author":"Horwitz","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"2019041607525577600_b10-0701115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"2019041607525577600_b11-0701115","first-page":"1","article-title":"Lymphoma classification: from REAL to WHO and beyond","volume-title":"Cancer: principles and practice of oncology updates","author":"Harris","year":"1999"},{"key":"2019041607525577600_b12-0701115","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1008200307625","article-title":"Peripheral T-cell lymphomas. Clinicopathologic study of 168 cases diagnosed according to the R.E.A.L. classification","volume":"8","author":"Ascani","year":"1997","journal-title":"Ann Oncol"},{"key":"2019041607525577600_b13-0701115","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"2019041607525577600_b14-0701115","first-page":"396","article-title":"Phenotypic analysis of peripheral T cell lymphoma among the Japanese","volume":"43","author":"Nakamura","year":"1993","journal-title":"Acta Pathol Jpn"},{"key":"2019041607525577600_b15-0701115","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019041607525577600_b16-0701115","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"2019041607525577600_b17-0701115","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Adv Hematol"},{"key":"2019041607525577600_b18-0701115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"key":"2019041607525577600_b19-0701115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/excr.1998.4027","article-title":"FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor","volume":"241","author":"Nakajima","year":"1998","journal-title":"Exp Cell Res"},{"key":"2019041607525577600_b20-0701115","volume-title":"Istodax (romidepsin) package insert","year":"2011"},{"key":"2019041607525577600_b21-0701115","volume-title":"Folotyn (pralatrexate) package insert","year":"2011"},{"key":"2019041607525577600_b22-0701115","doi-asserted-by":"crossref","first-page":"301","DOI":"10.7164\/antibiotics.47.301","article-title":"FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity","volume":"47","author":"Ueda","year":"1994","journal-title":"J Antibiot (Tokyo)"},{"key":"2019041607525577600_b23-0701115","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2019041607525577600_b24-0701115","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.3945\/jn.109.113332","article-title":"Dietary sulforaphane, a histone deacetylase inhibitor for cancer prevention","volume":"139","author":"Ho","year":"2009","journal-title":"J Nutr"},{"key":"2019041607525577600_b25-0701115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/BC20080158","article-title":"Histone deacetylases: salesmen and customers in the post-translational modification market","volume":"101","author":"Brandl","year":"2009","journal-title":"Biol Cell"},{"key":"2019041607525577600_b26-0701115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","article-title":"Histone deacetylase inhibitors in cancer treatment","volume":"13","author":"Vigushin","year":"2002","journal-title":"Anticancer Drugs"},{"key":"2019041607525577600_b27-0701115","doi-asserted-by":"crossref","first-page":"20436","DOI":"10.1074\/jbc.M000202200","article-title":"Histone deacetylases specifically down-regulate p53-dependent gene activation","volume":"275","author":"Juan","year":"2000","journal-title":"J Biol Chem"},{"key":"2019041607525577600_b28-0701115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737140.8.3.413","article-title":"Histone deacetylase inhibitors in lymphoma and solid malignancies","volume":"8","author":"Rasheed","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"2019041607525577600_b29-0701115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7","article-title":"Histone deacetylases, transcriptional control, and cancer","volume":"184","author":"Cress","year":"2000","journal-title":"J Cell Physiol"},{"key":"2019041607525577600_b30-0701115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2174\/138920007780655397","article-title":"Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application","volume":"8","author":"Santini","year":"2007","journal-title":"Curr Drug Metab"},{"key":"2019041607525577600_b31-0701115","first-page":"637","article-title":"Histone deacetylase inhibitors: apoptotic effects and clinical implications (review)","volume":"33","author":"Emanuele","year":"2008","journal-title":"Int J Oncol"},{"key":"2019041607525577600_b32-0701115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1756-8722-3-5","article-title":"Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents","volume":"3","author":"Tan","year":"2010","journal-title":"J Hematol Oncol"},{"key":"2019041607525577600_b33-0701115","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res"},{"key":"2019041607525577600_b34-0701115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2019041607525577600_b35-0701115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett"},{"key":"2019041607525577600_b36-0701115","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1073\/pnas.0500369102","article-title":"Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors","volume":"102","author":"Peart","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019041607525577600_b37-0701115","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1158\/1535-7163.MCT-07-2256","article-title":"Characterization of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin","volume":"7","author":"Newbold","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2019041607525577600_b38-0701115","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1073\/pnas.0702294104","article-title":"Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma","volume":"104","author":"Lindemann","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019041607525577600_b39-0701115","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/ijc.25218","article-title":"Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance","volume":"127","author":"Shao","year":"2010","journal-title":"Int J Cancer"},{"key":"2019041607525577600_b40-0701115","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"2019041607525577600_b41-0701115","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019041607525577600_b42-0701115","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","article-title":"Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma","volume":"15","author":"Woo","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b43-0701115","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1200\/JCO.2006.06.4964","article-title":"Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children\u2019s Oncology Group report","volume":"24","author":"Fouladi","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019041607525577600_b44-0701115","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"2019041607525577600_b45-0701115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2141.2009.07954.x","article-title":"Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma","volume":"148","author":"Bates","year":"2010","journal-title":"Br J Haematol"},{"key":"2019041607525577600_b46-0701115","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood.V98.9.2865","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report","volume":"98","author":"Piekarz","year":"2001","journal-title":"Blood"},{"key":"2019041607525577600_b47-0701115","first-page":"18","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b48-0701115","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","article-title":"A phase I trial of depsipeptide (FR901228) in patients with advanced cancer","volume":"2","author":"Marshall","year":"2002","journal-title":"J Exp Ther Oncol"},{"key":"2019041607525577600_b49-0701115","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019041607525577600_b50-0701115","article-title":"Complete responses with romidepsin in cutaneous T-cell lymphoma (CTCL) studies","author":"Whittaker"},{"key":"2019041607525577600_b51-0701115","article-title":"Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma (CTCL)","author":"Kim"},{"key":"2019041607525577600_b52-0701115","article-title":"Clinically relevant pruritus reduction in cutaneous T-cell lymphoma (CTCL) patients treated with romidepsin","author":"Kim"},{"key":"2019041607525577600_b53-0701115","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood.V120.21.3641.3641","article-title":"Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update","volume":"120","author":"Coiffier","year":"2012","journal-title":"Blood"},{"key":"2019041607525577600_b54-0701115","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V114.22.3701.3701","article-title":"Characterization of cyclic hematologic changes observed in patients with cutaneous T-cell lymphoma (CTCL) receiving romidepsin, a novel histone deacetylase (HDAC) inhibitor","volume":"114","author":"Whittaker","year":"2009","journal-title":"Blood"},{"key":"2019041607525577600_b55-0701115","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-06-1715","article-title":"HDAC inhibitors and cardiac safety","volume":"13","author":"Molife","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b56-0701115","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/1078-0432.CCR-05-2689","article-title":"Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors","volume":"12","author":"Shah","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b57-0701115","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood.V114.22.3709.3709","article-title":"Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin","volume":"114","author":"Cabell","year":"2009","journal-title":"Blood"},{"key":"2019041607525577600_b58-0701115","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood.V118.21.2680.2680","article-title":"Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin","volume":"118","author":"Godfrey","year":"2011","journal-title":"Blood"},{"key":"2019041607525577600_b59-0701115","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","article-title":"Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma","volume":"12","author":"Piekarz","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b60-0701115","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1182\/blood.V120.21.1617.1617","article-title":"A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the R0-CHOP Study","volume":"120","author":"Dupuis","year":"2012","journal-title":"Blood"},{"key":"2019041607525577600_b61-0701115","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10637-008-9190-8","article-title":"Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)","volume":"27","author":"Whitehead","year":"2009","journal-title":"Invest New Drugs"},{"key":"2019041607525577600_b62-0701115","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/annonc\/mdp270","article-title":"Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)","volume":"21","author":"Molife","year":"2010","journal-title":"Ann Oncol"},{"key":"2019041607525577600_b63-0701115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CGC.2006.n.018","article-title":"A phase II study of depsipeptide in refractory metastatic renal cell cancer","volume":"5","author":"Stadler","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"2019041607525577600_b64-0701115","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1158\/1078-0432.CCR-08-1007","article-title":"Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia","volume":"14","author":"Odenike","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"suppl 20","key":"2019041607525577600_b65-0701115","first-page":"26","article-title":"Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers","author":"Piekarz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019041607525577600_b66-0701115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/1078-0432.CCR-07-0135","article-title":"Clinical and molecular responses in lung cancer patients receiving romidepsin","volume":"14","author":"Schrump","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019041607525577600_b67-0701115","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1097\/JTO.0b013e3181ec1713","article-title":"Phase II study of the histone deacetylase inhibitor romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)","volume":"5","author":"Otterson","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2019041607525577600_b68-0701115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2010","journal-title":"Cancer"},{"key":"2019041607525577600_b69-0701115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/neuonc\/nor017","article-title":"A phase I\/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium study 03-03","volume":"13","author":"Iwamoto","year":"2011","journal-title":"Neuro Oncol"},{"key":"2019041607525577600_b70-0701115","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"2019041607525577600_b71-0701115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3109\/07357907.2012.675382","article-title":"Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors","volume":"30","author":"Jones","year":"2012","journal-title":"Cancer Invest"},{"key":"2019041607525577600_b72-0701115","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1182\/blood.V116.21.3937.3937","article-title":"The combination of histone deacetylase inhibitors and hypomethylating agents exhibits marked synergy in preclinical models of T-cell lymphoma","volume":"116","author":"Marchi","year":"2010","journal-title":"Blood"},{"key":"2019041607525577600_b73-0701115","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood.V114.22.1689.1689","article-title":"The combination of romidepsin and bortezomib results in synergistic induction of apoptosis in human B-lymphoma cell lines","volume":"114","author":"Deshpande","year":"2009","journal-title":"Blood"},{"key":"2019041607525577600_b74-0701115","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V112.11.3698.3698","article-title":"High response rates with the combination of bortezomib, dexamethasone, and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I\/II clinical trial","volume":"112","author":"Harrison","year":"2008","journal-title":"Blood"},{"key":"2019041607525577600_b75-0701115","doi-asserted-by":"crossref","first-page":"e2445","DOI":"10.1371\/journal.pone.0002445","article-title":"HDAC inhibitors act with 5-aza-2\u2032-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells","volume":"3","author":"Chai","year":"2008","journal-title":"PLoS One"},{"key":"2019041607525577600_b76-0701115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/JTO.0b013e318194fae7","article-title":"Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines","volume":"4","author":"Zhang","year":"2009","journal-title":"J Thorac Oncol"},{"key":"2019041607525577600_b77-0701115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1067\/mtc.2003.180","article-title":"Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: activation of the mitochondria-dependent death-signaling pathway","volume":"125","author":"Nguyen","year":"2003","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/70\/13\/1115\/28456506\/ajhp1115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T20:07:42Z","timestamp":1595966862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/70\/13\/1115\/5112612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,1]]},"references-count":77,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2013,7,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp120163","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,7,1]]},"published":{"date-parts":[[2013,7,1]]}}}